Oncolytics Biotech receives FDA Fast Track for pelareorep

An update from Oncolytics Biotech ( (ONCY) ) is now available.

On February 4, 2026, Oncolytics Biotech announced that the U.S. Food and Drug Administration granted Fast Track Designation for pelareorep in combination with bevacizumab and FOLFIRI as a second-line treatment for KRAS‑mutant, microsatellite-stable metastatic colorectal cancer, following an application submitted after a strategic shift toward gastrointestinal cancers. The designation is backed by clinical data showing a 33% objective response rate, median progression-free survival of 16.6 months, and median overall survival of 27 months for the pelareorep regimen, roughly double to triple standard-of-care outcomes in this difficult-to-treat patient group, which represents a global total addressable market estimated at $3‑5 billion annually. Oncolytics plans to initiate a controlled clinical study in this indication, with the first site expected to open in March and interim data targeted by year-end 2026, positioning pelareorep as a potentially important platform immunotherapy in gastrointestinal oncology and giving the company enhanced regulatory interaction that could expedite development timelines.

The most recent analyst rating on (ONCY) stock is a Hold with a $0.98 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.

Spark’s Take on ONCY Stock

According to Spark, TipRanks’ AI Analyst, ONCY is a Neutral.

The score is held back primarily by weak financial performance (no revenue, sizable losses, heavy cash burn, and a sharply reduced equity base that raises financing risk). Technicals are a near-term positive with price above major moving averages and positive momentum indicators, while valuation remains difficult to support due to the negative P/E and lack of dividend.

To see Spark’s full report on ONCY stock, click here.

More about Oncolytics Biotech

Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic designed to convert immunologically “cold” tumors “hot” by activating innate and adaptive immune responses. The company is advancing pelareorep in combination with chemotherapy and checkpoint inhibitors across metastatic gastrointestinal cancers, including colorectal and pancreatic cancer, where it has secured U.S. FDA Fast Track designations, and is seeking strategic partnerships to accelerate development and maximize commercial impact.

Average Trading Volume: 875,026

Technical Sentiment Signal: Sell

Current Market Cap: $104.2M

See more insights into ONCY stock on TipRanks’ Stock Analysis page.